Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms, Second Primary 1 Neoplasms 1

Interventions

Cyclophosphamide 44 Biopsy 35 Specimen Handling 34 Magnetic Resonance Spectroscopy 30 fludarabine 27 aldesleukin 26 Filgrastim 20 Carboplatin 20 Paclitaxel 19 fludarabine phosphate 17 Rituximab 17 Sirolimus 16 Cisplatin 16 Temozolomide 15 Radiotherapy 14 Etoposide 14 Bevacizumab 14 Prednisone 13 Gemcitabine 13 Docetaxel 13 Cytarabine 13 Erlotinib Hydrochloride 12 Fluorouracil 11 Vorinostat 10 Vincristine 10 Sorafenib 10 Electrocardiography 10 Doxorubicin 10 temsirolimus 9 pembrolizumab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × NIH × Clonidine × Clear all

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡